Publicaciones en colaboración con investigadores/as de Fundación Hospital Alcorcón (17)

2018

  1. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2016

  1. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

    Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400

2015

  1. Endocannabinoids and Neurodegenerative disorders: Parkinson’s disease, Huntington’s chorea, Alzheimer’s disease, and others

    Handbook of Experimental Pharmacology (Springer New York LLC), pp. 233-259

2014

  1. A restricted population of CB1 cannabinoid receptors with neuroprotective activity

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 22, pp. 8257-8262

  2. Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias

    British Journal of Pharmacology, Vol. 171, Núm. 6, pp. 1472-1489

2011

  1. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

    Brain, Vol. 134, Núm. 1, pp. 119-136

  2. Prospects for cannabinoid therapies in basal ganglia disorders

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1365-1378

2010

  1. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors

    Neurobiology of Disease, Vol. 37, Núm. 2, pp. 434-440

2009

  1. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

    GLIA, Vol. 57, Núm. 11, pp. 1154-1167

  2. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

    Brain, Vol. 132, Núm. 11, pp. 3152-3164

  3. The endocannabinoid system in neuropathological states

    International Review of Psychiatry, Vol. 21, Núm. 2 SPEC. ISS., pp. 172-180

2008

  1. Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa

    Journal of Histochemistry and Cytochemistry, Vol. 56, Núm. 5, pp. 511-516

  2. Colocalization of CB1 receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: Evidence for a role of these receptors in axonal growth and guidance

    Neuroscience, Vol. 153, Núm. 3, pp. 687-699

2007

  1. Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

    Trends in Pharmacological Sciences, Vol. 28, Núm. 1, pp. 39-45

2003

  1. Effects of perinatal exposure to Δ9-tetrahydrocannabinol on operant morphine-reinforced behavior

    Pharmacology Biochemistry and Behavior, Vol. 75, Núm. 3, pp. 577-584

2002

  1. The endogenous cannabinoid system and the basal ganglia: Biochemical, pharmacological, and therapeutic aspects

    Pharmacology and Therapeutics, Vol. 95, Núm. 2, pp. 137-152

2000

  1. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of Δ9- tetrahydrocannabinol-tolerant rats

    Journal of Neurochemistry, Vol. 74, Núm. 4, pp. 1627-1635